Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval Pharmaceutical TechnologyGlobalData analysts predicts that myostatin inhibitors like Isemblyd will be key drivers of growth within the SMA market in years to come.Rare DiseaseRead full story pharminent September 14, 2026 (Last updated: September 16, 2026) Pharmaceutical Technology GlobalData analysts predicts that myostatin inhibitors like Isemblyd will be key drivers of growth within the SMA market in years to come. Rare Disease Read full story Post navigation Previous: Psychedelic therapies ride wave of public favor into FDA hearingNext: Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand Related Stories Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026